Abstract
Introduction Inflammatory bowel disease (IBD), which includes Crohn’s disease (CD) and ulcerative colitis (UC), is a multifaceted illness with diverse manifestations. Current treatment strategies are inadequate, with low response rates, secondary loss of response, and serious side effects.
Methods We leveraged a large multiomics dataset (SPARC IBD) to compile a catalog of biomarkers for (i) disease severity, (ii) medication use, and (iii) response to a medication. Data were stratified based on IBD subtype (UC and CD) and tissue type; biomarker associations were identified using mixed-effects models to account for multiple medication groups, disease status (e.g., remission, active, etc.), and repeated sampling.
Results Our catalog lists thousands of potential biomarkers for disease severity (9,657), medication effect (293), and medication response (59). These biomarkers, both known and novel, span multiple diagnoses, tissues, and medications.
Conclusion These therapy-specific signatures will enable tracking of treatment response, diagnosis of disease severity, and identification of new therapeutic targets.
Competing Interest Statement
All authors were employees of Enveda Therapeutics, Inc. during the course of this work and have real or potential ownership interests in the company.
Funding Statement
NA
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The results published here are in whole from the Study of a Prospective Adult Research Cohort with IBD (SPARC IBD). SPARC IBD is a component of the Crohn's & Colitis Foundation's IBD Plexus data exchange platform. SPARC IBD enrolls patients with an established or new diagnosis of IBD from sites throughout the United States and links data collected from the electronic health record and study-specific case report forms. Patients also provide blood, stool, and biopsy samples at selected times during follow-up. The design and implementation of the SPARC IBD cohort have been previously described. The data is individual-level data anonymized by the Crohn's and Colitis Foundation.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data and code availability
SPARC IBD is available upon approved application to Crohn’s & Colitis Foundation IBD Plexus (https://www.crohnscolitisfoundation.org/ibd-plexus). We released the scripts and notebooks to reproduce the work at https://github.com/enveda/ccf-medication.
